Use of glutamine synthetase for treating hyperammonemia
AssigneeThoeris GmbH
InventorTamara Nicolson
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia. In particular the invention relates to the systemic administration of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods, and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.
Claims15
A microbial cell comprising a nucleic acid sequence encoding human glutamine synthetase, wherein the human glutamine synthetase is a fusion protein comprising
- i) glutamine synthetase;
- and
- ii) a peptide comprising the sequence MGSSHHHHHHGGGGS (SEQ ID NO:
- 8) or GSSHHHHHHGGGGS (SEQ ID NO:
- 9);
- wherein the glutamine synthetase of i) comprises SEQ ID NO:
- 1 or a variant thereof having glutamine synthetase activity and at least 90% sequence identity to SEQ ID NO:
- 1, or a variant thereof comprising SEQ ID NO:
- 1 except for the N terminal methionine at position 1 thereof and having glutamine synthetase activity.
Dependencies are inferred from the claim text.